Clinical trial
A Phase 2, Placebo-controlled, Double-blind, Randomized, Dose Ranging, Efficacy and Safety Study of Orally Administered Moxidectin in Adults With Scabies.
NCT05875441 is registered in ClinicalTrials.gov with Medicines Development for Global Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Placebo-controlled, Double-blind, Randomized, Dose Ranging, Efficacy and Safety Study of Orally Administered Moxidectin in Adults With Scabies.
- Lead sponsor
- Medicines Development for Global Health
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 23, 2023
- Completion date
- February 11, 2025
- Enrollment
- 200 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.